NSCLC tumors often feature heterogenous molecular drivers including MET, EGFR and ALK, rendering these malignancies suitable for validation of oncogene addiction-related changes in protein phosphorylations upon specific inhibition of a potentially addicting oncoprotein. The gene discussed is ALK; the disease is non-small cell lung carcinoma.